Druggability & Clinical Context
Druggability
Low
Score: 0.41
Druggability Analysis
Structural Tractability0.70
Key Metrics
PDB Structures:
3
Known Drugs:
2
Approved:
2
In Clinical Trials:
0
Drug Pipeline (2 compounds)
2 Approved
Therapeutic Areas:Oncology Immunology Ophthalmology
Druggability Rationale: The somatostatin (SST) receptor system demonstrates moderate druggability for neurodegeneration, with existing approved compounds like octreotide and lanreotide suggesting potential therapeutic utility. Structural data from three PDB entries and AlphaFold predictions provide molecular insights, while the moderate druggability score and existing receptor agonist/antagonist strategies indicate potential for targeted neurological interventions. The presence of active clinical trials exploring neuroprotective mechanisms further supports the target's translational potential.
Mechanism: Somatostatin is a peptide neurotransmitter that modulates neuronal signaling by inhibiting hormone release and neuronal excitability, with emerging evidence suggesting its potential neuroprotective role in neurodegenerative processes through regulation of inflammatory responses and synaptic plasticity. In neurodegeneration contexts, SST receptors may serve as modulators of neuroinflammatory cascades and potentially mitigate progressive neuronal damage through receptor-mediated signaling mechanisms.
Drug Pipeline (2 compounds)
2 Approved
Known Drugs:Octreotide (approved) — Neuroendocrine tumors
Lanreotide (approved) — Neuroendocrine tumors
Structural Data:PDB (3) ✓AlphaFold ✓Cryo-EM ✓
Binding Pocket Analysis:Receptor interaction surface
Clinical Trials (8)
Relevant trials from ClinicalTrials.gov
By Phase
PHASE2: 1 · PHASE3: 2 · PHASE4: 2 · Unknown: 3
PHASE4
NCT00108355
n=29
Ascites, Cirrhosis
Interventions: Albumin, Intravenous Saline Infusion (Albumin pla, Midodrine
Sponsor: US Department of Veterans Affairs | Started: 2003-12
PHASE4
NCT01917773
n=13
Colonic Motility Index, Constipation
Interventions: Octreotide, Bisacodyl
Sponsor: Indiana University | Started: 2013-08
Unknown
NCT05171751
n=50
Congenital Hyperinsulinaemic Hypoglycaem, Octreotide Adverse Reaction
Interventions: Octreotide Injection
Sponsor: Beijing Children's Hospital | Started: 2021-11-01
Unknown
NCT00222092
n=300
Post-ERCP Acute Pancreatitis
Sponsor: University of Ioannina | Started: 2005-09
Unknown
NCT00234520
n=225
Acromegaly
Sponsor: Ipsen | Started: 2003-05
PHASE3
NCT00092287
n=4
Malignant Carcinoid Syndrome
Interventions: lanreotide Autogel (somatostatin analogu, Sandostatin long acting release (LAR) De
Sponsor: Ipsen | Started: 2004-07
PHASE3
NCT02354768
n=19
High Output Stoma
Interventions: Effects of lanreotide with current anti-, Effects of current anti-diarrheal treatm
Sponsor: University Hospital, Strasbourg, France | Started: 2015-10-22
PHASE2
NCT00227773
Gastrointestinal Carcinoid Tumor, Islet Cell Carcinoma
Interventions: octreotide acetate, vatalanib, anti-cytokine therapy
Sponsor: Eastern Cooperative Oncology Group